|Bid||18.01 x 3200|
|Ask||21.05 x 900|
|Day's Range||18.24 - 19.01|
|52 Week Range||11.55 - 21.23|
|Beta (3Y Monthly)||2.11|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
When it comes to stocks that can shoot up overnight, biotechs are the name of the game. This group’s extreme volatility lies in the fact that a single piece of good news like promising study results can cause share prices to climb to new heights, while the reverse also holds true.As a result, it’s often difficult to determine if names in this industry represent compelling investments. That being said, there are tools available that can help gauge which biotech stocks are poised for substantial long-term growth.Using TipRanks’ Best Stocks to Buy tool, we were able to zero in on 3 biotech stocks that have achieved a “Perfect 10” Smart Score. The metric weighs a variety of factors and combines them into a single numerical score, with 10 being the highest. Not to mention each has earned a ‘Strong Buy’ consensus rating, according to all of the ratings published by analysts in the last three months. Alexion Pharmaceuticals (ALXN)Alexion wants to improve the lives of patients suffering from rare diseases such as atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), hypophosphatasia (HPP) and other conditions. While best known for its Soliris therapy to treat aHUS, a disease that causes abnormal blood clots to form in small blood vessels in the kidneys, the company has recently expanded its pipeline and has several candidates in development.In its most recent quarter, ALXN highlighted its deals with Eidos, Stealth and Achillion as part of its efforts to diversify its offerings. It also expects to add four new clinical stage assets, including two in Phase 3 development. Bearing this in mind, management raised its total revenue guidance to between $4.86 billion to $4.89 billion. If achieved, this would demonstrate an 18% year-over-year gain at the midpoint of the range.With all of these promising developments, it’s no wonder that nine analysts have published bullish calls in just the last ten days. One of the analysts singing ALXN’s praises is Citigroup’s Mohit Bansal. He argues that the biotech is a growth stock trading like a value stock. He adds that the “strong” revenue guidance and recently expanded pipeline may be of interest to incremental investors. As a result, Bansal reiterated his Buy rating. (To watch Bansal’s track record, click here)The rest of the Street appears to echo the analyst’s sentiment. In just the last three months, ALXN has received 16 Buy ratings and 2 Holds, giving it a ‘Strong Buy’ analyst consensus. Its $155 average price target suggests 48% upside potential. (See Alexion stock analysis on TipRanks) Immunomedics (IMMU)Immunomedics uses antibody-based therapies to develop treatments for cancer, autoimmune and other diseases. With the company recently launching studies back in April and May, buzz surrounding this biotech has been building.The company recently announced the launch of its registrational Phase 3 study for patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2–) metastatic breast cancer. The study of its IMMU-132 drug will feature patients that have experienced failure of at least two but no more than four prior chemotherapy regimens for metastatic disease. IMMU also launched a Phase 2 open label study of its sacituzumab govitecan therapy to treat advanced solid tumors.On top of these trials, the biotech is recruiting for a Phase 2 trial of sacituzumab govitecan for patients with metastatic (Stage IV) urothelial cancer after failure of a platinum-based regimen and/or anti-PD-1/PD-L1 based therapies. While investors will have to wait for the results from the trials, Piper Jaffray analyst Joseph Catanzaro sees significant upside in store for IMMU.“We believe Immunomedics is very well-positioned within triple-negative breast cancer and urothelial bladder cancer,” he commented. Based on all of the above factors, the analyst reiterated his Buy rating and $20 price target. This price target conveys his confidence in IMMU’s ability to surge 23% over the next twelve months. (To watch Catanzaro’s track record, click here)With only Buy ratings assigned in the last three months, the word on the Street is clear: IMMU is a ‘Strong Buy’. Additionally, it boasts 58% upside potential thanks to its $26 average price target. (See Immunomedics stock analysis on TipRanks) Coherus Biosciences (CHRS)By developing biosimilar treatments, Coherus hopes to give patients access to more affordable drugs. A biosimilar drug is a medicine or therapy that is very similar to an already approved biological medicine. While it may seem counterintuitive to develop a drug that resembles something already on the market, they are beneficial in that they provide more treatment options and potentially reduce costs.Following the January 3 launch of its UDENYCA drug to decrease the occurrence of infection in patients receiving anti-cancer drugs, the company has been performing solidly. CHRS saw its UDENYCA net sales reach about $120 million in the first half of 2019. Management stated that this figure was bolstered by strong exit unit market share of 13% at the end of June.All of this led to a 125% increase in net product revenue from the first quarter to the second. With the company developing a therapy similar to Amgen’s Enbrel drug to treat rheumatoid arthritis, some analysts tell investors CHRS is primed for strong long-term growth.Barclays’ Balaji Prasad is one of the analysts maintaining a bullish thesis. While stating that shares experienced some weakness following AMGN’s favorable Enbrel patent ruling against Novartis, he remains very optimistic. He views any share weakness as an opportunity to add a "fundamentally sound company”. This played into his decision to reiterate his Buy rating and $31 price target. (To watch Prasad’s track record, click here)Similarly, other analysts take a bullish approach when it comes to CHRS. It earns a ‘Strong Buy’ Street consensus based on the 6 Buy ratings assigned over the last three months. The biotech stock’s potential twelve-month gain also comes in at 91% according to its $32 average price target. (See Coherus stock analysis on TipRanks)
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]
Immunomedics, Inc. (NASDAQ: IMMU) is a biopharma company focusing on the development of antibody-drug conjugates, or ADCs. Sacituzumab is in the most advanced stage of clinical development for treating patients with metastatic triple negative breast cancer, or mTNBC. On July 18, 2018, the FDA accepted the BLA for the regulatory review of sacituzumab govitecan as a treatment option for mTNBC in the third-line setting and above, fixing the PDUFA action date at Jan. 18, 2019.
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. An Immunomedics, Inc. (NASDAQ: IMMU) director and an executive each stepped up to the buy window this past week. The company released positive trial data at the European Society for Medical Oncology (ESMO) Annual Congress.
Whilst it may not be a huge deal, we thought it was good to see that Bryan Ball, who is a company insider, recently...
Immunomedics (IMMU) presents interim data on sacituzumab govitecan in patients with metastatic urothelial cancer. The company also inks two deals.
Seattle Genetics stock broke out bullishly Monday after the biotech company presented "striking" results for a bladder cancer treatment. Its colon cancer treatment also impressed analysts.
At a cancer-medicine conference in Barcelona this week, researchers presented data. There was new evidence for rival immunotherapies from Merck and Bristol-Myers Squibb. Seattle Genetics bested Immunomedics in treating bladder cancer. Amgen suffered a disappointment.
The five-day European Society of Medical Oncology, or ESMO, Congress 2019 is set to conclude Tuesday in Barcelona, Spain. Touted as a congress where the exchange of translational cancer science of excellence ...
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Dova Pharmaceuticals (NASDAQ: DOVA ) shares ...
Seattle Genetics was rising Monday after analysts at Stifel raised their price target on the stock to $95 from $69 on positive results from its bladder cancer treatment candidate. In a presentation at the European Society for Medical Oncology meeting in Barcelona over the weekend, rival Immunomedics' sacituzumab govitecan showed a 29% response rate, short of the 44% response rate Seattle Genetics' competing drug showed. Shares of Immunomedics were falling 10.8% to $12.77.
Immunomedics shares are falling after the company's bladder-cancer-treatment candidate showed a response rate lower than that of a competitor's. In a presentation at the European Society for Medical Oncology meeting in Barcelona over the weekend, Immunomedics' sacituzumab govitecan showed a 29% response rate, short of the 44% response rate Seattle Genetics' competing drug showed. Analysts at Piper Jaffray, who have an overweight rating on Immunomedics, said both drugs are likely to be important bladder-cancer treatments, and they urged investors to wait for "more mature data" before deciding on the product.
Immunomedics (IMMU) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Actions speak louder than words, as the saying goes. And when it comes to insiders, that certainly seems to be the case. If we track informative insider buy transactions, we can get an idea of the stocks that insiders see as compelling investing opportunities right now. As insiders have access to a wealth of company information, these insights can be very valuable when deciding which stocks to buy or sell. With that in mind we took a closer look at three stocks insiders are snapping up right now: Immunomedics (IMMU)Immunomedics focuses on the development of antibody-drugs for the treatment of cancer. Most notably sacituzumab has received Breakthrough Therapy designation from the FDA for the treatment of patients with triple-negative breast cancer (TNBC) who failed previous therapies. It’s also granted the drug fast track designation for lung cancer treatment. Shares have surged 12% in the last five days, and that’s partly down to an influx of insider money. Most notably, corporate director and owner venBio Select Advisor LLC recently picked up a whopping $13.5 million worth of stock. That brings venBio’s total holding of IMMU to just over $298 million. And it’s not just insiders that are bullish. The stock also shows a ‘Strong Buy’ analyst consensus with an average price target of $23- indicating that further upside potential of 54% lies ahead. “As we expect sacituzumab to address a major unmet need in the treatment of r/r mTNBC [metastatic triple negative breast cancer] next year, we continue to think that IMMU is undervalued for its potential” comments Cowen & Co analyst Phil Nadeau. “We continue to expect sacituzumab will become a standard mTNBC treatment upon its approval” the analyst added. He notes that Daiichi’s DS-1062a has the potential to be long-term competition to IMMU's sacituzumab- but reassures investors that IMMU is clearly well ahead. “Given sacituzumab's several-year lead, it will be incumbent upon DS-1062a to show meaningful advantages in order to displace it” the analyst writes. Fastly Inc (FSLY)Cloud computing services provider Fastly is a newcomer to the markets. The company, which helps companies deliver online content more quickly, debuted on the NYSE back in May. Its IPO was a great success; the company sold 11.25 million shares at $16 each, bringing returns of $180 million. Since the IPO shares have surged to the current price of $20.55.And now we can see that insiders are already pouring more money into this fast-growing tech stock. Abdiel Capital Management, one of the company’s owners, has just picked up a further $7.62 million of FSLY stock. This brings the total holding to $78.8 million. No doubt this move would make sense to five-star analyst Brad Reback of Stifel Nicolaus. He initiated coverage of the stock with a buy rating and $25 price target (22% upside potential). The analyst contends: “In the coming years, we believe Fastly can leverage its superior technological approach to drive continued strong net new customer additions and expand its wallet share among its existing installed base.” Combined with a large market opportunity and the ability to further penetrate international markets, Reback is confident that Fastly can sustain at least a 30% top-line growth profile. Myovant Sciences (MYOV)Myovant Sciences is a clinical-stage biopharma developing therapies for women’s health and endocrine diseases. Shares have crashed 47% year-to-date, with the selloff prompted by the release of relugolix phase 3 uterine fibroids data. Investors are concerned about Abbvie’s (ABBV) uterine fibroid rival, Orlissa.However, insiders are demonstrating their confidence in the company. In the last three months insiders have bought a whopping $160 million of shares. That includes a $45,000 purchase from director Sebelius Kathleen, as well as $20 million from owner Viking Global Investors. Indeed, all ten transactions in the last month are positive insider buy transactions- with only one insider sell transaction recorded four months ago.Furthermore, the Street is also staying onside. All five analysts covering the stock rate Myovant a ‘buy.’ That gives the stock its ‘Strong Buy’ analyst consensus. Meanwhile their average price target of $26 indicates massive upside potential of 194%. Analysts argue that the stock looks oversold at current levels, with Barclays analyst Geoffrey Meacham saying he still believes Myovant’s relugolix has a favorable profile compared to rival offerings. Meanwhile five-star Evercore ISI analyst Ravi Mehrotra is anticipating revenues of $944M for relugolix by 2023 due to its "commercial advantage of a one-a-day pill." Discover more Hot Insider Trading Stocks here